Safety, Tolerability and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma
Status:
Completed
Trial end date:
2018-07-10
Target enrollment:
Participant gender:
Summary
This study of DSF-Cu in combination with TMZ for recurrent GBM will evaluate the antitumor
effect in patients who have recurrent GBM. Patients will take DSF-Cu daily during their
routine standard of care with TMZ therapy for approximately 6 months. Patients will be
evaluated for response every 8 weeks. Patients will be followed up 2 years after the last
dose of DSF-Cu.